X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.
波士頓，2024年11月14日(GLOBE NEWSWIRE) -- x4製藥（納斯達克：XFOR）是一家致力於改善罕見免疫系統疾病患者生活的公司，今天宣佈管理層將參加2024年11月18-19日在紐約舉行的Stifel 2024醫療保健會議。
| Stifel 2024 Healthcare Conference | |
| Date: | Monday, November 18, 2024 |
| Time: | 4:10PM ET |
| Format: | Fireside Chat |
| Location: | Lotte New York Palace, New York |
| Webcast Link | |
| 2024年史蒂夫爾醫療保健大會 | |
| 日期： | 2024年11月18日星期一 |
| 時間： | 東部時間 4:10 PM |
| 格式： | 爐邊聊天 |
| 地點： | 紐約樂天宮，紐約 |
| 網絡研討會鏈接 | |
A link for this live webcast will also be accessible through the "events & presentations" page in the investors section of X4 Pharmaceuticals' website. After the conclusion of the conference, a webcast replay will be available through the same link.
在x4製藥網站的投資者部分，"活動和演示"頁面也將提供此次直播網絡研討會的鏈接。會議結束後，可以通過相同鏈接訪問網絡研討會重播。
The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Stifel representative to request meetings.
公司將在本次會議期間提供一對一的會議。有意向的投資者應聯繫他們的Stifel代表以請求會議。
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .
關於x4製藥
X4製藥正在爲罕見免疫系統疾病患者提供進展，並開發和推廣創新治療方案，以滿足他們的重大未滿足需求。利用我們在CXCR4和免疫系統生物學方面的專業知識，我們已成功開發了mavorixafor，並在其第一個適應症中獲得了美國批准 - XOLREMDI（mavorixafor）膠囊。我們還在評估mavorixafor在其他潛在適應症中的使用。X4製藥的總部位於美國馬薩諸塞州波士頓，研究中心位於奧地利維也納。欲了解更多信息，請訪問我們的網站。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司聯繫人：
Jose Juves
企業和患者事務負責人
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投資者聯繫人：
Daniel Ferry
LifeSci Advisors董事總經理
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals
資料來源：X4 Pharmaceuticals
譯文內容由第三人軟體翻譯。